top of page

Pfrieger's Digest | Issue 12 - August 2024 – December 2024

Writer's picture: ANPDFANPDF

Summaries of latest research advances related to Niemann-Pick diseases, acid sphingomyelinase deficiency (ASMD) and Niemann-Pick type C disease (NPCD), based on selected peer-reviewed publications in scientific journals.



By Frank W. Pfrieger, PhD

Institute of Cellular and Integrative Neurosciences

Centre National de la Recherche Scientifique / University of Strasbourg

Strasbourg, France



Read the full article here:


The latest Pfrieger’s Digest covers key research on Niemann-Pick diseases, including 82 publications on NPC and 37 on ASMD. Highlights include studies on biomarkers like neuron-specific enolase and lysosphingolipids, advancements in patient registries, and breakthroughs in animal models. Key findings:

  • MRI biomarkers may improve NPC diagnosis.

  • Newborn screening in Italy suggests NPC incidence is 1 in 137,506 births.

  • Novel treatments, such as dipyridamole, show partial success in improving NPC symptoms in mice.

  • A humanized NPC1 mouse model opens doors to better preclinical research.

  • Patient registries are highlighted as critical for understanding rare diseases.


Please feel free to distribute and forward this issue, and to send feedback to: fw-pfrieger@gmx.de or frank.pfrieger@unistra.fr


 

Support research for a cure of Niemann-Pick disease type C in Australia:


25 views0 comments

Related Posts

See All
ANPDF Logo

The ANPDF is dedicated to providing support and hope for a better future to all those living with Niemann-Pick disease.

  • Facebook
  • Instagram
  • Twitter
  • LinkedIn
  • Youtube

We have so many exciting things going on,

be the first to find out!

Thanks for submitting!

©2024 by Australian NPC Disease Foundation Inc.

Australian NPC Disease Foundation Inc is registered with the Australian Tax Office as an Income Tax Exempt Charity. All donations over $2 are tax deductible.

ACNC-Registered-Charity-Logo_RGB
bottom of page